The safety of incretin based drugs

BMJ. 2014 Apr 24:348:g2779. doi: 10.1136/bmj.g2779.
No abstract available

Publication types

  • Editorial
  • Comment

MeSH terms

  • Diabetes Mellitus, Type 2 / drug therapy*
  • Dipeptidyl-Peptidase IV Inhibitors / adverse effects*
  • Female
  • Glucagon-Like Peptide 1 / analogs & derivatives*
  • Humans
  • Hypoglycemic Agents / adverse effects*
  • Incretins / adverse effects*
  • Incretins / therapeutic use*
  • Male
  • Pancreatitis / chemically induced*

Substances

  • Dipeptidyl-Peptidase IV Inhibitors
  • Hypoglycemic Agents
  • Incretins
  • Glucagon-Like Peptide 1